Dexmedetomidine as Adjuvant for FNB in TKA

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

November 5, 2018

Study Completion Date

November 10, 2018

Conditions
Nerve BlockDexmedetomidine
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine added to lower concentration of ropivacaine for postoperative analgesia in FNB

PROCEDURE

ultrasound-guided femoral nerve block

ultrasound-guided femoral nerve block, a single bolous of 20 ml ropivacaine (concentration 0.2% for H group or 0.1% for L group) before surgery followed by continuous femoral nerve block using an infusion rate of ropivacaine 0.2% 5 ml/h for postoperative analgesia started right after surgery

DEVICE

intravenous patient-controlled analgesia pump with morphine

All subjects received intravenous patient-controlled analgesia (IV-PCA) pumps to measure additional morphine consumption, which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.

PROCEDURE

Continuous femoral nerve block

All the continuous femoral nerve block infusion regimes in the pump were connected to CFNB catheter, which contained only ropivacaine with different concentrations (ropivacaine 0.1% for L group and LD group; ropivacaine 0.2% for H group, 5 ml/h).

Trial Locations (2)

510000

Department of Anesthesiology, First affiliated hospital of Sun Yat-Sen University, Guangzhou

Unknown

Department of Anesthesiology, First affiliated hospital of Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

First Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT03658421 - Dexmedetomidine as Adjuvant for FNB in TKA | Biotech Hunter | Biotech Hunter